← All trials
NCT04586985
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 26, 2020
- Primary completion
- Sep 21, 2021
- Completion date
- Sep 21, 2021
- First posted
- Oct 14, 2020
- Last posted
- Nov 25, 2020
- Enrollment
- 88
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fulcrum TherapeuticsLead sponsor
- Fulcrum TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.